Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor β resistance and acquire paracrine mitogenic stimulation during progression

Cancer Research

Volumn 67, Issue 7, 2007, Pages 3135-3144

  Corsino, Patrick ^a   Davis, Bradley ^a   Law, Mary ^a   Chytil, Anna ^b   Forrester, Elizabeth ^b   Nørgaard, Peter ^c   Teoh, Nicole ^a   Law, Brian ^a,d  

^a UNIVERSITY OF FLORIDA   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; HYBRID PROTEIN; PROTEIN P130; S6 KINASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; CYCLIN D1; RBL2 PROTEIN, MOUSE; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST EPITHELIUM; BREAST HYPERPLASIA; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; MITOGENESIS; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; BIOSYNTHESIS; ENZYME ACTIVATION; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; FEMALE; FIBROBLAST; GENETICS; HYPERPLASIA; METABOLISM; MOUSE; PATHOLOGY; PROMOTER REGION; TRANSGENIC MOUSE; UDDER; VIROLOGY;

ANIMALS; CYCLIN D1; CYCLIN-DEPENDENT KINASE 2; DISEASE PROGRESSION; ENZYME ACTIVATION; FEMALE; FIBROBLASTS; HEPATOCYTE GROWTH FACTOR; HYPERPLASIA; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; PROMOTER REGIONS (GENETICS); RECOMBINANT FUSION PROTEINS; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA-LIKE PROTEIN P130; TRANSFORMING GROWTH FACTOR BETA;

EID: 34248195589     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3815     Document Type: Article

References (45)

1. Akli S, Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther 2003;2:S38-47.
2. Xia W, Chen JS, Zhou X, et al. Phosphorylation/ cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 2004;10:3815-24.
3. Winters ZE, Hunt NC, Bradburn MJ, et al. Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer. Association with prognosis. Eur J Cancer 2001;37:2405-12.
4. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.
5. Han S, Park K, Kim HY, Lee MS, Kim HJ, Kim YD. Reduced expression of p27Kip1 protein is associated with poor clinical outcome of breast cancer patients treated with systemic chemotherapy and is linked to cell proliferation and differentiation. Breast Cancer Res Treat 1999;55:161-7.
6. Blain SW, Massague J. Breast cancer banishes p27 from nucleus. Nat Med 2002;8:1076-8.
7. Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8: 1136-44.
8. Coletta RD, Christensen K, Reichenberger KJ, et al. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci U S A 2004;101: 6478-83.
9. Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 2004;10:4270-5s.
10. Deans AJ, Khanna KK, McNees CJ, Mercurio C, Heierhorst J, McArthur GA. Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. Cancer Res 2006;66: 8219-26.
11. Wesierska-Gadek J, Schmid G. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein. Expert Opin Investig Drugs 2006;15:23-38.
12. 1 cyclin expression in breast cancer cells. Oncogene 1998; 16:2865-78.
13. Sutherland RL, Musgrove EA. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res 2002;4:14-7.
14. Chytil A, Waltner-Law M, West R, et al. Construction of a cyclin D1-2 fusion protein to model the biological functions of cyclin D1-2 complexes. J Biol Chem 2004; 279:47688-98.
15. Matsui Y, Halter SA, Holt JT, Hogan BL, Coffey RJ. Development of mammary hyperplasia and neoplasia in MMTV-TGF α transgenic mice. Cell 1990;61:1147-55.
16. Ip MM, Asch BB, editors. Methods in mammary gland biology and breast cancer research. New York (NY), 10013: Kluwer Academic/Plenum Publishers; 2000. p. 317.
17. Law BK, Chytil A, Dumont N, et al. Rapamycin potentiates transforming growth factor β-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol 2002;22: 8184-98.
18. Hall C, Nelson DM, Ye X, et al. HIRA, the human homologue of yeast Hir1p and Hir2p, is a novel cyclin-cdk2 substrate whose expression blocks S-phase progression. Mol Cell Biol 2001;21:1854-65.
19. Brown KA, Roberts RL, Arteaga CL, Law BK. Transforming growth factor-β induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein. Breast Cancer Res 2004;6:R130-9.
20. Law M, Forrester E, Chytil A, et al. Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res 2006;66:1070-80.
21. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB. An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 1994;216:276-84.
22. Bacus SS, Gudkov AV, Esteva FJ, Yarden Y. Expression of erbB receptors and their ligands in breast cancer: implications to biological behavior and therapeutic response. Breast Dis 1999;11:63-75.
23. Hulit J, Lee RJ, Russell RG, Pestell RG. ErbB-2-induced mammary tumor growth: the role of cyclin D1 and p27Kip1. Biochem Pharmacol 2002;64:827-36.
24. Lee RJ, Albanese C, Fu M, et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 2000;20:672-83.
25. Bowe DB, Kenney NJ, Adereth Y, Maroulakou IG. Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E. Oncogene 2002;21:291-8.
26. Nelsen CJ, Kuriyama R, Hirsch B, et al. Short-term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy. J Biol Chem 2005;280:768-76.
27. Duensing A, Liu Y, Tseng M, Malumbres M, Barbacid M, Duensing S. Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication. Oncogene 2006;25:2943-9.
28. Desmouliere A, Guyot C, Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 2004;48:509-17.
29. Walker RA. The complexities of breast cancer desmoplasia. Breast Cancer Res 2001;3:143-5.
30. Ohtani H, Kuroiwa A, Obinata M, Ooshima A, Nagura H. Identification of type I collagen-producing cells in human gastrointestinal carcinomas by non-radioactive in situ hybridization and immunoelectron microscopy. J Histochem Cytochem 1992;40:1139-46.
31. Ronnov-Jessen L, Van Deurs B, Nielsen M, Petersen OW. Identification, paracrine generation, and possible function of human breast carcinoma myofibroblasts in culture. In vitro Cell Dev Biol 1992;28A:273-83.
32. Ronnov-Jessen L, Petersen OW. Induction of α-smooth muscle actin by transforming growth factor-β 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest 1993;68:696-707.
33. Ronnov-Jessen L, Petersen OW, Koteliansky VE, Bissell MJ. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 1995;95: 859-73.
34. Beauchamp RD, Coffey RJ, Jr., Lyons RM, Perkett EA, Townsend CM, Jr., Moses HL. Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. Cancer Res 1991;51:5253-60.
35. Neaud V, Faouzi S, Guirouilh J, et al. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology 1997;26:1458-66.
36. Guirouilh J, Castroviejo M, Balabaud C, Desmouliere A, Rosenbaum J. Hepatocarcinoma cells stimulate hepatocyte growth factor secretion in human liver myofibroblasts. Int J Oncol 2000;17:777-81.
37. De Wever O, Nguyen QD, Van Hoorde L, et al. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J 2004;18:1016-8.
38. Lewis MP, Lygoe KA, Nystrom ML, et al. Tumour-derived TGF-β1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br J Cancer 2004;90:822-32.
39. Sato Y, Tsuboi R, Lyons R, Moses H, Rifkin DB. Characterization of the activation of latent TGF-β by cocultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol 1990; 111:757-63.
40. Steinman RA, Wentzel A, Lu Y, Stehle C, Grandis JR. Activation of Stat3 by cell confluence reveals negative regulation of Stat3 by cdk2. Oncogene 2003; 22:3608-15.
41. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225:1-26.
42. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345-55.
43. Matsuyama S, Iwadate M, Kondo M, et al. SB-431542 and Gleevec inhibit transforming growth factor-β-induced proliferation of human osteosarcoma cells. Cancer Res 2003;63:7791-8.
44. Halder SK, Beauchamp RD, Datta PK. A specific inhibitor of TGF-β receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 2005;7:509-21.
45. Ge R, Rajeev V, Ray P, et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-β type I receptor kinase in vivo. Clin Cancer Res 2006; 12:4315-30.